AU767411B2 - Method and composition for prevention of scar formation in glaucoma filtration bleb and drainage fistula - Google Patents
Method and composition for prevention of scar formation in glaucoma filtration bleb and drainage fistula Download PDFInfo
- Publication number
- AU767411B2 AU767411B2 AU33402/00A AU3340200A AU767411B2 AU 767411 B2 AU767411 B2 AU 767411B2 AU 33402/00 A AU33402/00 A AU 33402/00A AU 3340200 A AU3340200 A AU 3340200A AU 767411 B2 AU767411 B2 AU 767411B2
- Authority
- AU
- Australia
- Prior art keywords
- prostaglandin
- pga
- pgj
- derivative
- eye
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 208000010412 Glaucoma Diseases 0.000 title claims abstract description 28
- 238000000034 method Methods 0.000 title claims abstract description 24
- 208000002352 blister Diseases 0.000 title claims abstract description 22
- 230000036573 scar formation Effects 0.000 title claims abstract description 16
- 206010016717 Fistula Diseases 0.000 title claims abstract description 14
- 230000003890 fistula Effects 0.000 title claims abstract description 14
- 238000001914 filtration Methods 0.000 title claims description 26
- 239000000203 mixture Substances 0.000 title claims description 18
- 230000002265 prevention Effects 0.000 title claims description 8
- 150000003180 prostaglandins Chemical class 0.000 claims abstract description 58
- 238000001356 surgical procedure Methods 0.000 claims abstract description 41
- -1 isopropyl ester Chemical class 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 8
- 150000002148 esters Chemical class 0.000 claims description 7
- BGKHCLZFGPIKKU-UHFFFAOYSA-N (13E,15S)-15-hydroxy-9-oxo-prosta-10,13-dienoic acid Natural products CCCCCC(O)C=CC1C=CC(=O)C1CCCCCCC(O)=O BGKHCLZFGPIKKU-UHFFFAOYSA-N 0.000 claims description 5
- 239000013543 active substance Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 238000011200 topical administration Methods 0.000 claims 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 29
- 230000004410 intraocular pressure Effects 0.000 description 26
- 238000011282 treatment Methods 0.000 description 23
- 239000003981 vehicle Substances 0.000 description 18
- 150000001875 compounds Chemical class 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 12
- 238000012360 testing method Methods 0.000 description 11
- 206010061218 Inflammation Diseases 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 230000004054 inflammatory process Effects 0.000 description 8
- 210000002950 fibroblast Anatomy 0.000 description 7
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 6
- 210000001742 aqueous humor Anatomy 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 230000037390 scarring Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 206010030348 Open-Angle Glaucoma Diseases 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000001028 anti-proliverative effect Effects 0.000 description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 239000003889 eye drop Substances 0.000 description 3
- 229940012356 eye drops Drugs 0.000 description 3
- 229960004857 mitomycin Drugs 0.000 description 3
- 210000003733 optic disk Anatomy 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 210000001585 trabecular meshwork Anatomy 0.000 description 3
- 201000004569 Blindness Diseases 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- BZKFMUIJRXWWQK-UHFFFAOYSA-N Cyclopentenone Chemical compound O=C1CCC=C1 BZKFMUIJRXWWQK-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 125000005907 alkyl ester group Chemical group 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 210000002159 anterior chamber Anatomy 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- 210000000795 conjunctiva Anatomy 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 229940097362 cyclodextrins Drugs 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- XXUPXHKCPIKWLR-JHUOEJJVSA-N isopropyl unoprostone Chemical compound CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(=O)OC(C)C XXUPXHKCPIKWLR-JHUOEJJVSA-N 0.000 description 2
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000002637 mydriatic agent Substances 0.000 description 2
- 230000002911 mydriatic effect Effects 0.000 description 2
- 125000006574 non-aromatic ring group Chemical group 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000001603 reducing effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 229950008081 unoprostone isopropyl Drugs 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010027646 Miosis Diseases 0.000 description 1
- 206010067013 Normal tension glaucoma Diseases 0.000 description 1
- 206010030043 Ocular hypertension Diseases 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
- AHANXAKGNAKFSK-PDBXOOCHSA-N all-cis-icosa-11,14,17-trienoic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCCCC(O)=O AHANXAKGNAKFSK-PDBXOOCHSA-N 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000002927 anti-mitotic effect Effects 0.000 description 1
- 229940006138 antiglaucoma drug and miotics prostaglandin analogues Drugs 0.000 description 1
- 239000003080 antimitotic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000009412 basement excavation Methods 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000005786 degenerative changes Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BORBLDJNKYHVJP-FXBDTBDDSA-N dolichodial Chemical compound C[C@H]1CC[C@H](C(=C)C=O)[C@@H]1C=O BORBLDJNKYHVJP-FXBDTBDDSA-N 0.000 description 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 1
- IQLUYYHUNSSHIY-HZUMYPAESA-N eicosatetraenoic acid Chemical compound CCCCCCCCCCC\C=C\C=C\C=C\C=C\C(O)=O IQLUYYHUNSSHIY-HZUMYPAESA-N 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000013532 laser treatment Methods 0.000 description 1
- 229960001160 latanoprost Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 208000018769 loss of vision Diseases 0.000 description 1
- 231100000864 loss of vision Toxicity 0.000 description 1
- 201000002978 low tension glaucoma Diseases 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 230000003547 miosis Effects 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000008289 pathophysiological mechanism Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- UQOQENZZLBSFKO-POPPZSFYSA-N prostaglandin J2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)C=CC1=O UQOQENZZLBSFKO-POPPZSFYSA-N 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229960004906 thiomersal Drugs 0.000 description 1
- 231100000925 very toxic Toxicity 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 229940002639 xalatan Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/908—Mechanical repair performed/surgical
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/915—Therapeutic or pharmaceutical composition
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Compounds Of Unknown Constitution (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9900672 | 1999-02-25 | ||
| SE9900672A SE9900672D0 (sv) | 1999-02-25 | 1999-02-25 | Method and composition for prevention of scar formation in glaucoma filtration bleb and drainage fistula |
| PCT/SE2000/000357 WO2000050040A1 (en) | 1999-02-25 | 2000-02-23 | Method and composition for prevention of scar formation in glaucoma filtration bleb and drainage fistula |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU3340200A AU3340200A (en) | 2000-09-14 |
| AU767411B2 true AU767411B2 (en) | 2003-11-06 |
Family
ID=20414625
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU33402/00A Ceased AU767411B2 (en) | 1999-02-25 | 2000-02-23 | Method and composition for prevention of scar formation in glaucoma filtration bleb and drainage fistula |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6495563B1 (enExample) |
| EP (1) | EP1161245B1 (enExample) |
| JP (1) | JP2003521467A (enExample) |
| AT (1) | ATE279197T1 (enExample) |
| AU (1) | AU767411B2 (enExample) |
| CA (1) | CA2363131A1 (enExample) |
| DE (1) | DE60014869T2 (enExample) |
| SE (1) | SE9900672D0 (enExample) |
| WO (1) | WO2000050040A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090162417A1 (en) * | 2007-12-21 | 2009-06-25 | Cook Incorporated | Drug eluting ocular conformer |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0242580A2 (en) * | 1986-03-13 | 1987-10-28 | The Trustees Of Columbia University In The City Of New York | Use of A, B and C prostaglandins and derivatives thereof to treat ocular hypertension and glaucoma |
| WO1990002553A1 (en) * | 1988-09-06 | 1990-03-22 | Pharmacia Ab | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
| WO1996009055A1 (en) * | 1994-09-21 | 1996-03-28 | Pharmacia & Upjohn Ab | New use of prostaglandins |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3981880A (en) | 1969-03-14 | 1976-09-21 | The Upjohn Company | Racemic prostaglandins of the 2-series and analogs thereof |
| US3954844A (en) | 1975-01-03 | 1976-05-04 | G. D. Searle & Co. | (5Z,13E,15S)-15-Hydroxy-11-oxoprosta-5,9.13-trien-1-oic acid and esters |
| JPS58216155A (ja) | 1982-06-10 | 1983-12-15 | Ono Pharmaceut Co Ltd | 新規なプロスタグランジンｄ類似化合物 |
| DE3876050T2 (de) | 1987-09-18 | 1993-03-25 | Ueno Seiyaku Oyo Kenkyujo Kk | Okulare hypotensivagenzien. |
| EP0580268B1 (en) | 1988-10-01 | 1998-01-14 | R-Tech Ueno Ltd. | Ocular hypotensive agents |
| CA2071137A1 (en) | 1991-07-10 | 1993-01-11 | Clarence C. Lee | Composition and method for revitalizing scar tissue |
| SE9401087D0 (sv) * | 1994-03-31 | 1994-03-31 | Pharmacia Ab | New prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
-
1999
- 1999-02-25 SE SE9900672A patent/SE9900672D0/xx unknown
-
2000
- 2000-02-23 WO PCT/SE2000/000357 patent/WO2000050040A1/en not_active Ceased
- 2000-02-23 AU AU33402/00A patent/AU767411B2/en not_active Ceased
- 2000-02-23 CA CA002363131A patent/CA2363131A1/en not_active Abandoned
- 2000-02-23 EP EP00911536A patent/EP1161245B1/en not_active Expired - Lifetime
- 2000-02-23 JP JP2000600651A patent/JP2003521467A/ja not_active Withdrawn
- 2000-02-23 AT AT00911536T patent/ATE279197T1/de not_active IP Right Cessation
- 2000-02-23 DE DE60014869T patent/DE60014869T2/de not_active Expired - Fee Related
- 2000-02-23 US US09/913,849 patent/US6495563B1/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0242580A2 (en) * | 1986-03-13 | 1987-10-28 | The Trustees Of Columbia University In The City Of New York | Use of A, B and C prostaglandins and derivatives thereof to treat ocular hypertension and glaucoma |
| WO1990002553A1 (en) * | 1988-09-06 | 1990-03-22 | Pharmacia Ab | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
| WO1996009055A1 (en) * | 1994-09-21 | 1996-03-28 | Pharmacia & Upjohn Ab | New use of prostaglandins |
Also Published As
| Publication number | Publication date |
|---|---|
| DE60014869T2 (de) | 2006-03-09 |
| DE60014869D1 (de) | 2004-11-18 |
| JP2003521467A (ja) | 2003-07-15 |
| AU3340200A (en) | 2000-09-14 |
| SE9900672D0 (sv) | 1999-02-25 |
| WO2000050040A1 (en) | 2000-08-31 |
| EP1161245A1 (en) | 2001-12-12 |
| WO2000050040A8 (en) | 2003-02-06 |
| US6495563B1 (en) | 2002-12-17 |
| CA2363131A1 (en) | 2000-08-31 |
| EP1161245B1 (en) | 2004-10-13 |
| ATE279197T1 (de) | 2004-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0569046B1 (en) | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension | |
| US5952378A (en) | Methods and means for drug administration | |
| CA2310661C (en) | Ep2-receptor agonists as neuroprotective agents for the eye | |
| US6090847A (en) | EP2 -receptor agonists as neuroprotective agents for the eye | |
| AU725677B2 (en) | 8-iso-prostaglandins for glaucoma therapy | |
| JPS63313728A (ja) | プロスタグランジンとアドレナリン性遮断剤との組合せからなる眼圧降下用組成物 | |
| WO1998007435A1 (en) | Eye treatments using synthetic thyroid hormone compositions | |
| WO1993024121A1 (fr) | Medicament pour le glaucome | |
| Hayashi et al. | Eicosanoids as a new class of ocular hypotensive agents. 2. Comparison of the apparent mechanism of the ocular hypotensive effects of A and F type prostaglandins. | |
| AU767411B2 (en) | Method and composition for prevention of scar formation in glaucoma filtration bleb and drainage fistula | |
| CA2200481C (en) | Method and means for prevention and treatment of secondary cataract | |
| CN1268344C (zh) | 葛根素眼用凝胶及其制备方法 | |
| WO2003026744A1 (en) | The use of epothilones and analogs in conjunction with ophthalmic surgery | |
| Sorbera et al. | Bimatoprost | |
| US20040058899A1 (en) | Use of epothilones and analogs in conjunction with ophthalmic surgery | |
| JP2008503577A (ja) | 眼圧を降下するためのアブノーマル・カンナビジオール化合物 | |
| JPWO2000038689A1 (ja) | 高眼圧症あるいは緑内障の処置用医薬組成物 | |
| AU717608C (en) | Eye treatments using synthetic thyroid hormone compositions | |
| Bandyopadhyay | Case study: latanoprost: isopropylester of a prostaglandin F2α analog |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |